CD274 and neoplasm: In addition, a phase 1a/1b study of ramucirumab plus pembrolizumab in patients with previously treated GC/GEJ17 and a phase 2 study of lenvatinib plus pembrolizumab in patients with GC/GEJ30 reported increased response rates and longer median progression-free survival for patients with PD-L1 levels in tumours by CPS ≥1% compared with CPS <1%.